MedPath

Omega 3 Supplementation in Children With Non Alcoholic Fatty Liver

Not Applicable
Completed
Conditions
Fatty Liver
Interventions
Dietary Supplement: omega 3 fatty acids
Registration Number
NCT04281121
Lead Sponsor
Ain Shams University
Brief Summary

this is a prospective, interventional, open-label, randomized study on the efficacy of omega 3 fatty acids supplementation in Egyptian children with non-alcoholic fatty liver disease who had been selected from nutrition and outpatient clinic at Pediatric hospital, Ain Shams University

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
60
Inclusion Criteria

Children between 5 - 16 years old with diffusely hyper echogenic liver at ultrasonography were included in the study.

Read More
Exclusion Criteria
  • Patients with secondary causes of steatosis including total parenteral nutrition, drugs causing fatty liver disease for example steroids, hepatitis A, B, C, cytomegalovirus, Epstein-Barr virus infections, autoimmune liver disease, metabolic liver diseases, Wilson's disease, and alpha-1-antitrypsin deficiency.
  • Patients currently taking fish oil supplements.
  • Patients with systemic illness such as cardiac and kidney diseases.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
supplementedomega 3 fatty acidsLife style modification, diet regimen and Omega-3 fatty acids supplementation
non supplementedomega 3 fatty acidsLife style modification and diet regimen
Primary Outcome Measures
NameTimeMethod
grade of fatty liver in children3 month

improvement

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Pediatrics hospital Ain shams University

🇪🇬

Cairo, Egypt

© Copyright 2025. All Rights Reserved by MedPath